Treatment of urinary tract infections in gynecological patients. A randomized study comparing pivampicillin-pivmecillinam with trimethoprim-sulphamethoxazole.
Eighty-two gynecological patients with clinical signs of a lower urinary tract infection (UTI) were randomized to 10 days' treatment with either a fixed combination of pivampicillin-pivmecillinam (PAPM) or trimethoprim-sulphamethoxazole (TMPS). The effect of treatment could be evaluated in 25 patients on PAPM and in 19 on TMPS, who had bacteriologically verified UTI and who completed treatment and check-ups. All strains were sensitive in vitro to the respective antibiotic combination used. Treatment eradicated the original pathogen in 75-80% of the cases, 64% of the patients on PAPM and 47% on TMPS having sterile urine 3 weeks after end of treatment. Side effects could be evaluated in 76 patients. Two patients on PAPM and 8 on TMPS had to discontinue treatment due to side effects. Including abnormal values for hematology, liver and renal parameters, significantly fewer side effects (p = 0.038) were noted on PAPM (7/40) than on TMPS (15/36).
D000293:Adolescent; D000328:Adult; D000368:Aged; D000561:Amdinocillin Pivoxil / Q000627:therapeutic use*; D000667:Ampicillin / Q000031:analogs & derivatives*; D001424:Bacterial Infections / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008875:Middle Aged; D010397:Penicillanic Acid / Q000627:therapeutic use*; D010917:Pivampicillin / Q000627:therapeutic use*; D011897:Random Allocation; D013420:Sulfamethoxazole / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D004338:Drug Combinations; D010917:Pivampicillin; D000561:Amdinocillin Pivoxil; D000667:Ampicillin; D010397:Penicillanic Acid; D014295:Trimethoprim; D013420:Sulfamethoxazole